Patents by Inventor Paul Workman
Paul Workman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240004729Abstract: A real time contextual event notification system that ingests events as streams from any authorized entity applies rules to the event streams, determines a context of an end-user who is a recipient of a targeted notification, and provides notifications to the end-user in accordance with the context. The event streams may come from multiple sources and rules may be applied to provide real time contextual information associated with the end-user.Type: ApplicationFiled: June 30, 2023Publication date: January 4, 2024Inventors: Paul Workman, Ryan Coram, Brendan Killen, Chris Schnurr
-
Publication number: 20230419953Abstract: A real-time contextual event notification system ingests events as streams from any authorized entity, applies rules to the event streams, determines a context of an end-user who is a recipient of a targeted notification, and provides notifications to the end-user in accordance with the context. The event streams may come from multiple sources, and rules may be applied to provide real-time contextual information associated with the end user. One such event stream includes detected linguistic and/or acoustic events during a phone call between two or more persons.Type: ApplicationFiled: June 22, 2023Publication date: December 28, 2023Inventors: Chris Schnurr, Paul Workman, Kirsty Meredith, Brendan Killen, Curtis Cunningham, Chris O'Donnell, Inês Ferreira, Peter Connolly, Tim Furnell, Assaf Arbely, Duane Wright
-
Patent number: 11572901Abstract: The subject matter of this specification can be embodied in, among other things, an electrohydraulic positioning control system that includes a shuttle valve configured to direct fluid flow between a selectable one of a first fluid port and a second fluid port, and a fluid outlet configured to be fluidically connected to a fluid actuator, a first servo valve controllable to selectably permit and block flow between the first fluid port, a fluid source, and a fluid drain, a second servo valve controllable to selectably permit and block flow between the second fluid port, the fluid source, and the fluid drain, a first servo controller configured to provide a first health signal and control the first servo valve based on a second health signal, and a second servo controller configured to provide the second health signal and control the second servo valve based on the first health signal.Type: GrantFiled: March 15, 2021Date of Patent: February 7, 2023Assignee: Woodward, Inc.Inventors: Jonathan Paul Workman, Gregory A. Molenaar, Marek Kazimierz Redzina, Krzysztof Sutkowski
-
Publication number: 20210285466Abstract: The subject matter of this specification can be embodied in, among other things, an electrohydraulic positioning control system that includes a shuttle valve configured to direct fluid flow between a selectable one of a first fluid port and a second fluid port, and a fluid outlet configured to be fluidically connected to a fluid actuator, a first servo valve controllable to selectably permit and block flow between the first fluid port, a fluid source, and a fluid drain, a second servo valve controllable to selectably permit and block flow between the second fluid port, the fluid source, and the fluid drain, a first servo controller configured to provide a first health signal and control the first servo valve based on a second health signal, and a second servo controller configured to provide the second health signal and control the second servo valve based on the first health signal.Type: ApplicationFiled: March 15, 2021Publication date: September 16, 2021Inventors: Jonathan Paul Workman, Gregory A. Molenaar, Marek Kazimierz Redzina, Krzysztof Sutkowski
-
Patent number: 8846696Abstract: The present invention relates to compounds of formula 1 or pharmaceutically acceptable salts thereof, wherein one of R1 and R2 is methyl, ethyl or isopropyl, and the other is H; R3 and R4 are each independently H, branched or unbranched C1-C6 alkyl, or aryl, and wherein at least one of R3 and R4 is other than H; R5 is a branched or unbranched C1-C5 alkyl group or a C1-C6 cycloalkyl group, each of which may be optionally substituted with one or more OH groups; R6, R7, R8 and R9 are each independently H, halogen, NO2, OH, OMe, CN, NH2, COOH, CONH2, or SO2NH2. A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula 1, and the use of said compounds in treating proliferative disorders, viral disorders, stroke, alopecia, CNS disorders, neurodegenerative disorders, or diabetes.Type: GrantFiled: June 23, 2009Date of Patent: September 30, 2014Assignees: Cyclacel Limited, Cancer Research Technology LimitedInventors: Peter Martin Fischer, Michael Jarman, Edward McDonald, Bernard Nutley, Florence Raynaud, Stuart Wilson, Paul Workman
-
Patent number: 7674823Abstract: The invention relates to the use of compounds of formula (I) and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, in the preparation of a medicament for inhibiting the activity of DNA-PK, wherein R1 and R2 are independently hydrogen, an optionally substituted C1-7 alkyl group, C3-20 heterocyclyl group, or C5-20 aryl group, or may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; X and Y are selected from CR4 and O, O and CR?4 and NR?4 and N, where the unsaturation is in the appropriate place in the ring, and where one of R3 and R4 or R?4 is an optionally substituted C3-20 heteroaryl or C5-20 aryl group, and the other of R3 and R4 or R?4 is H, or R3 and R4 or R?4 together are —A—B—, which collectively represent a fused optionally substituted aromatic ring. The compounds also selectively inhibit the activity of DNA-PK compared to PI 3-kinase and/or ATM.Type: GrantFiled: June 5, 2007Date of Patent: March 9, 2010Assignee: Cancer Research Technology LimitedInventors: Niall Morrison Barr Martin, Graeme Cameron Murray Smith, Roger John Griffin, Bernard Thomas Golding, Ian Robert Hardcastle, David Richard Newell, Hilary Alan Calvert, Nicola Jane Curtin, Laurent Jean Martin Rigoreau, Xiao-ling Fan Cockcroft, Vincent Junior Ming-lai Loh, Paul Workman, Florence Irene Raynaud, Bernard Paul Nutley
-
Publication number: 20090325983Abstract: The present invention relates to compounds of formula 1 or pharmaceutically acceptable salts thereof, wherein one of R1 and R2 is methyl, ethyl or isopropyl, and the other is H; R3 and R4 are each independently H, branched or unbranched C1-C6 alkyl, or aryl, and wherein at least one of R3 and R4 is other than H; R5 is a branched or unbranched C1-C5 alkyl group or a C1-C6 cycloalkyl group, each of which may be optionally substituted with one or more OH groups; R6, R7, R8 and R9 are each independently H, halogen, NO2, OH, OMe, CN, NH2, COOH, CONH2, or SO2NH2. A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula 1, and the use of said compounds in treating proliferative disorders, viral disorders, stroke, alopecia, CNS disorders, neurodegenerative disorders, or diabetes.Type: ApplicationFiled: June 23, 2009Publication date: December 31, 2009Applicants: CYCLACEL LIMITED, CANCER RESEARCH TECHNOLOGY LIMITEDInventors: Peter Martin FISCHER, Michael JARMAN, Edward MCDONALD, Bernard NUTLEY, Florence RAYNAUD, Stuart WILSON, Paul WORKMAN
-
Patent number: 7612079Abstract: The present invention relates to compounds of formula I or a pharmaceutically acceptable salt thereof wherein R2 is 2-hydroxymethylpyrrolidin-1-yl, or NHCH(R4)CH(R3)OH, wherein R3 is hydrogen or methyl and R4 is methyl, ethyl or isopropyl; R6 is 3-nitrophenylamino, 3,4-dimethoxybenzylamino, 3-iodobenzyl-amino, pyrid-2-yl-methylamino, pyrid-4-yl-methylamino or indan-5-amino; R9 is isopropyl or cyclopentanyl. In a further aspect, the invention relates to pharmaceutical compositions comprising said compounds, and the use thereof in treating antiproliferative disorders and or viral disorders.Type: GrantFiled: December 18, 2003Date of Patent: November 3, 2009Assignees: Cyclacel Limited, Cancer Research Technology LimitedInventors: Peter Martin Fischer, Mike Jarman, Ted McDonald, Bernard Nutley, Florence Raynaud, Stuart Wilson, Paul Workman
-
Publication number: 20090270427Abstract: The present invention relates to compounds of formula 1 or pharmaceutically acceptable salts thereof, wherein one of R1 and R2 is methyl, ethyl or isopropyl, and the other is H; R3 and R4 are each independently H, branched or unbranched C1-C6 alkyl, or aryl, and wherein at least one of R3 and R4 is other than H; R5 is a branched or unbranched C1-C5 alkyl group or a C1-C6 cycloalkyl group, each of which may be optionally substituted with one or more OH groups; R6, R7, R8 and R9 are each independently H, halogen, NO2, OH, OMe, CN, NH2, COOH, CONH2, or SO2NH2. A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula 1, and the use of said compounds in treating proliferative disorders, viral disorders, CNS disorders, diabetes, stroke, alopecia or neurodegenerative disorders.Type: ApplicationFiled: April 30, 2009Publication date: October 29, 2009Applicants: Cyclacel Limited, Cancer Research Technology LimitedInventors: Peter Martin FISHER, Michael JARMAN, Edward MCDONALD, Bernard NUTLEY, Florence RAYNAUD, Stuart WILSON, Paul WORKMAN
-
Patent number: 7582642Abstract: The present invention relates to compounds of formula 1 or pharmaceutically acceptable salts thereof, wherein one of R1 and R2 is methyl, ethyl or isopropyl, and the other is H; R3 and R4 are each independently H, branched or unbranched C1-C6 alkyl, or aryl, and wherein at least one of R3 and R4 is other than H; R5 is a branched or unbranched C1-C5 alkyl group or a C1-C6 cycloalkyl group, each of which may be optionally substituted with one or more OH groups; R6, R7, R8 and R9 are each independently H, halogen, NO2, OH, OMe, CN, NH2, COOH, CONH2, or SO2NH2. A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula 1, and the use of said compounds in treating proliferative disorders, viral disorders, stroke, alopecia, CNS disorders, neurodegenerative disorders, or diabetes.Type: GrantFiled: January 11, 2005Date of Patent: September 1, 2009Assignees: Cyclacel Limited, Cancer Research Technology LimitedInventors: Peter Martin Fischer, Michael Jarman, Edward McDonald, Bernard Nutley, Florence Raynaud, Stuart Wilson, Paul Workman
-
Patent number: 7544689Abstract: The present invention relates to compounds of formula I or pharmaceutically acceptable salts thereof, wherein one of R1 and R2 is methyl, ethyl or isopropyl, and the other is H; R3 and R4 are each independently H, branched or un branched C1-C6 alkyl, or aryl, and wherein at least one of R3 and R4 is other than H; R5 is a branched or unbranched C1-C5 alkyl group or a C1-C6 cycloalkyl group, each of which may be optionally substituted with one or more OH groups; R6, R7, R8 and R9 are each independently H, halogen, NO2, OH, OMe, CN, NH2, COOH, CONH2, or SO2NH2. A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula 1, and the use of said compounds in treating proliferative disorders, viral disorders, CNS disorders, diabetes, stroke, alopecia or neurodegenerative disorders.Type: GrantFiled: September 28, 2005Date of Patent: June 9, 2009Assignees: Cyclacel Limited, Cancer Research Technology LimitedInventors: Peter Martin Fischer, Michael Jarman, Edward McDonald, Bernard Nutley, Florence Raynaud, Stuart Wilson, Paul Workman
-
Publication number: 20070238729Abstract: The invention relates to the use of compounds of formula (I) and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, in the preparation of a medicament for inhibiting the activity of DNA-PK, wherein R1 and R2 are independently hydrogen, an optionally substituted C1-7 alkyl group, C3-20 heterocyclyl group, or C5-20 aryl group, or may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; X and Y are selected from CR4 and O, O and CR?4 and NR?4 and N, where the unsaturation is in the appropriate place in the ring, and where one of R3 and R4 or R?4 is an optionally substituted C3-20 heteroaryl or C5-20 aryl group, and the other of R3 and R4 or R?4 is H, or R3 and R4 or R?4 together are -A-B—, which collectively represent a fused optionally substituted aromatic ring. The compounds also selectively inhibit the activity of DNA-PK compared to PI 3-kinase and/or ATM.Type: ApplicationFiled: June 5, 2007Publication date: October 11, 2007Applicant: CANCER RESEARCH TECHNOLOGY LIMITEDInventors: Niall Martin, Graeme Smith, Roger Griffin, Bernard Golding, Ian Hardcastle, David Newell, Hilary Calvert, Nicola Curtin, Laurent Rigoreau, Xiao-ling Cockcroft, Vincent Junior Loh, Paul Workman, Florence Raynaud, Bernard Nutley
-
Patent number: 7247734Abstract: The present invention pertains to the use of certain 3,4-diarylpyazoles of formula (I), both in vitro and in vivo, to inhibit heat shock protein 90 (HSP90), and in the treatment of conditions mediated by HSP90, including, for example, cancer; wherein: Ar3 is independently: a C5-20aryl group, and is optionally substituted; Ar4 is independently: a C5-20aryl group, and is optionally substituted; R5 is independently: hydrogen; halo; hydroxyl; ether; formyl; acyl; carboxy; ester; acyloxy; oxycarbonyloxy; amido; acylamido; aminocarbonyloxy; tetrazolyl; amino; nitro; cyano; azido; sulfhydryl; thioether; sulfonamide; C1-7alkyl; C3-20heterocycyl; or C5-20aryl; R<SP>N</SP> is independently: —H; C1-7alkyl; C3-20heterocycyl; or, C5-20aryl; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.Type: GrantFiled: December 19, 2002Date of Patent: July 24, 2007Assignees: Vernalis (Cambridge) Limited, Cancer Research Technology Ltd., Institute of Cancer Research of Royal Cancer HospitalInventors: Martin James Drysdale, Brian William Dymock, Xavier Barril-Alonso, Paul Workman, Laurence Harris Pearl, Chrisostomos Prodromou, Edward McDonald
-
Patent number: 7226918Abstract: The invention relates to the use of compounds of formula (I) and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, in the preparation of a medicament for inhibiting the activity of DNA-PK, wherein R1 and R2 are independently hydrogen, an optionally substituted C1-7 alkyl group, C3-20 heterocyclyl group, or C5-20 aryl group, or may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; X and Y are selected from CR4 and O, O and CR?4 and NR?4 and N, where the unsaturation is in the appropriate place in the ring, and where one of R3 and R4 or R?4 is an optionally substituted C3-20 heteroaryl or C5-20 aryl group, and the other of R3 and R4 or R?4 is H, or R3 and R4 or R?4 together are -A-B—, which collectively represent a fused optionally substituted aromatic ring. The compounds also selectively inhibit the activity of DNA-PK compared to PI 3-kinase and/or ATM.Type: GrantFiled: August 14, 2002Date of Patent: June 5, 2007Assignee: Cancer Research Technology LimitedInventors: Niall Morrison Barr Martin, Graeme Cameron Murray Smith, Roger John Griffin, Bernard Thomas Golding, Ian Robert Hardcastle, David Richard Newell, Hilary Alan Calvert, Nicola Jane Curtin, Laurent Jean Martin Rigoreau, Xiao-ling Fan Cockcroft, Vincent Junior Ming-lai Loh, Paul Workman, Florence Irene Raynaud, Bernard Paul Nutley
-
Publication number: 20070010432Abstract: This invention relates the identification of a novel co-factor (termed ‘Aha1’) that interacts with the molecular chaperone Heat shock protein 90 (Hsp90) and stimulates Hsp90 activity. Various assay methods and therapeutic applications based on this interaction are provided.Type: ApplicationFiled: February 4, 2003Publication date: January 11, 2007Inventors: Paul Workman, Wynne Ahern, Laurence Pearl, Chrisostomos Prodromou
-
Patent number: 7105518Abstract: The present invention provides compounds of formula (I) and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, wherein R1 and R2 are independently hydrogen, an option ally substituted C1-7 alkyl group, C3-20 heterocyclyl group, or C5-20 aryl group, or may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; and R3 is an optionally substituted C3-20 heterocyclyl or C5-20 aryl group, and their use as pharmaceuticals, particularly in treating diseases which are retroviral mediated or ameliorated by the inhibition of DNA-PK,Type: GrantFiled: August 14, 2002Date of Patent: September 12, 2006Assignee: Cancer Research Technology LimitedInventors: Niall Morrison Barr Martin, Graeme Cameron Murray Smith, Roger John Griffin, Bernard Thomas Golding, Ian Robert Hardcastle, Laurent Jean Martin Rigoreau, David Richard Newell, Hilary Alan Calvert, Nicola Jane Curtin, Paul Workman, Florence Irene Raynaud, Bernard Paul Nutley
-
Publication number: 20060188898Abstract: The present invention relates to pharmacodynamic markers for CDKIs including the candidate 2,6,9-tri-substituted purine known as roscovitine. The identity of these markers facilitates the convenient identification of roscovitine-like activity both in vitro and in vivo.Type: ApplicationFiled: September 29, 2005Publication date: August 24, 2006Inventors: Simon Green, Paul Workman, Steven Whittaker
-
Publication number: 20060183760Abstract: The present invention relates to compounds of formula I or pharmaceutically acceptable salts thereof, wherein one of R1 and R2 is methyl, ethyl or isopropyl, and the other is H; R3 and R4 are each independently H, branched or un branched C1-C6 alkyl, or aryl, and wherein at least one of R3 and R4 is other than H; R5 is a branched or unbranched C1-C5 alkyl group or a C1-C6 cycloalkyl group, each of which may be optionally substituted with one or more OH groups; R6, R7, R8 and R9 are each independently H, halogen, NO2, OH, OMe, CN, NH2, COOH, CONH2, or SO2NH2. A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula 1, and the use of said compounds in treating proliferative disorders, viral disorders, CNS disorders, diabetes, stroke, alopecia or neurodegenerative disorders.Type: ApplicationFiled: September 28, 2005Publication date: August 17, 2006Inventors: Peter Fischer, Michael Jarman, Edward McDonald, Bernard Nutley, Florence Raynaud, Stuart Wilson, Paul Workman
-
Publication number: 20050256142Abstract: The present invention relates to compounds of formula 1 or pharmaceutically acceptable salts thereof, wherein one of R1 and R2 is methyl, ethyl or isopropyl, and the other is H; R3 and R4 are each independently H, branched or unbranched C1-C6 alkyl, or aryl, and wherein at least one of R3 and R4 is other than H; R5 is a branched or unbranched C1-C5 alkyl group or a C1-C6 cycloalkyl group, each of which may be optionally substituted with one or more OH groups; R6, R7, R8 and R9 are each independently H, halogen, NO2, OH, OMe, CN, NH2, COOH, CONH2, or SO2NH2. A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula 1, and the use of said compounds in treating proliferative disorders, viral disorders, CNS disorders, diabetes, stroke, alopecia or neurodegenerative disorders.Type: ApplicationFiled: January 11, 2005Publication date: November 17, 2005Inventors: Peter Fischer, Michael Jarman, Edward McDonald, Bernard Nutley, Florence Raynaud, Stuart Wilson, Paul Workman
-
Publication number: 20050222230Abstract: The present invention pertains to the use of certain 3,4-diarylpyrazoles of formula (I), both in vitro and in vivo, to inhibit heat shock protein 90 (HSP90), and in the treatment of conditions mediated by HSP90, including, for example, cancer; wherein: Ar3 is independently: a C5-20aryl group, and is optionally substituted; Ar4 is independently: a C5-20aryl group, and is optionally substituted; R5 is independently: hydrogen; halo; hydroxy; ether; formyl; acyl; carboxy; ester, acyloxy; oxycarbonyloxy; amido; acylamido; aminocarbonyloxy; tetrazolyl; amino; nitro; cyano; azido; sulfhydryl; thioether; sulfonamido; C1-7alkyl; C3-20heterocycyl; or C5-20aryl; R<SP>N</SP> is independently: —H; C1-7alkyl; C3-20heterocycyl; or, C5-20aryl; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.Type: ApplicationFiled: December 19, 2002Publication date: October 6, 2005Applicants: VERNALIS (CAMBRIDGE) LIMITED, CANCER RESEARCH TECHNOLOGY LTD., THE INSTITUE OF CANCER RESEARCHInventors: Martin Drysdale, Brian Dymock, Xavier Barril-Alonso, Paul Workman, Laurence Pearl, Chrisostomos Prodromou, Edward Macdonald